KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EPS (Weighted Average and Diluted) (2016 - 2025)

Biogen has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at -$0.35 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.35 for Q4 2025, down 119.13% from a year ago — trailing twelve months through Dec 2025 was $8.79 (down 21.45% YoY), and the annual figure for FY2025 was $8.79, down 21.38%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.35 at Biogen, down from $3.17 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BIIB hit a ceiling of $7.84 in Q3 2022 and a floor of -$0.47 in Q3 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $2.68 (2023), compared with a mean of $2.96.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 665.96% in 2024 and later tumbled 119.13% in 2025.
  • Biogen's EPS (Weighted Average and Diluted) stood at $2.5 in 2021, then skyrocketed by 52.0% to $3.8 in 2022, then plummeted by 55.0% to $1.71 in 2023, then rose by 7.02% to $1.83 in 2024, then tumbled by 119.13% to -$0.35 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.35 (Q4 2025), $3.17 (Q3 2025), and $4.33 (Q2 2025) per Business Quant data.